Overview

Orthotopic seeding of human tumor cell lines allows assessment of tumor development in a complimentary environment and provides efficacy evaluation in a preclinical tumor model mimicking the disease process in humans. This allows for a more representative strategy of primary tumor growth, metastatic activity and response to therapy scenarios to be more accurately quantified.

Disease progress can be evaluated through a variety of methods including clinical signs, survival study design and our imaging platform utilizing both in vivo and ex vivo capabilities.

Charles River offers the following orthotopic tumor models:

  • Renal Sub-Capsule Orthotopic Model of Cancer
    The renal orthotopic tumor model was developed for the efficacy evaluation of novel anticancer compounds using a tumor growth delay model that mimics the disease process in humans. Cell lines used in this tumor model include 786-O.
  • Intracranial Orthotopic Model
    Intracranial injection of tumor cells mimics clinical responses to tumor growth. Test agent effects are evaluated based on clinical observations and sample analyses. We have used the U87MG human glioma models successfully in mice.
  • Intrasplenic Hepatic Colonization Model
    Orthotopic seeding of human tumor cell lines allows assessment of tumor development in a hepatic environment and provides efficacy evaluation in a preclinical tumor model mimicking the disease process in humans. This allows for a more representative picture of tumor growth and response to therapy scenario to be realized.
  • Orthotopic Breast Tumor Model
    BT474, MCF-7, MDA-MB231 or MX-1 cancer lines can be injected directly into the mammary fat pad of the mouse in this orthotopic tumor model of cancer.
  • Systemic Leukemia/Lymphoma Model
    In this orthotopic tumor model, Raji-B, MV4-11, Granta-519 or Ramos tumor cells are intravenously injected into the tail vein. Clinical signs associated with progression of tumor include impairment of hind limb function, ocular proptosis and weight loss.